Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing
- 23 September 2021
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 59 (8) , 793-800
Abstract
Background Traditional medical genetics models are unable to meet the growing demand for germline genetic testing (GT) in patients with exocrine pancreatic cancer (PC). This study investigates the impact of an ambulatory oncology clinic-based GT model. Methods From 2012 to 2021, patients with PC were prospectively enrolled and considered for GT. Two chronological cohorts were compared: (1) the preuniversal genetic testing (pre-UGT) cohort, which received GT based on clinical criteria or family history; and (2) the post-UGT cohort, where an 86-gene panel was offered to all patients with PC. Results Of 847 eligible patients, 735 (86.8%) were enrolled (pre-UGT, n=579; post-UGT, n=156). A higher proportion of the post-UGT cohort received prospective GT (97.4% vs 58.5%, pConclusion A point-of-care GT model is feasible and expedites access to GT for patients with PC. Strategies to increase the uptake of cascade testing are needed to maximise the clinical impact of an oncology clinic-based GT model.Keywords
Funding Information
- Quebec Cancer Consortium
- Pancreatic Cancer Canada Foundation
- Santé
- Terry Fox Research Institute
This publication has 39 references indexed in Scilit:
- Genetic Counselors’ Experiences Regarding Communication of Reproductive Risks with Autosomal Recessive Conditions found on Cancer PanelsJournal of Genetic Counseling, 2015
- Familial Pancreatic AdenocarcinomaHematology/Oncology Clinics of North America, 2015
- Establishing a Clinic-Based Pancreatic Cancer and Periampullary Tumour Research Registry in QuebecCurrent Oncology, 2015
- Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic CancerGastroenterology, 2015
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersBritish Journal of Cancer, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Family Communication of BRCA1/2 Results and Family Uptake of BRCA1/2 Testing in a Diverse Population of BRCA1/2 CarriersJournal of Genetic Counseling, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Testing Participation in BRCA1/2 -Positive Families: Initiator Role of Index CasesGenetic Testing, 2003